Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma

Documenti analoghi

• The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography
  di: Miwa Kawanaka, et al.
  Pubblicazione: (2025)
• Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2024)
• A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
  di: Tetsu Tomonari, et al.
  Pubblicazione: (2025)
• Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2025)
• Vascular endothelial growth factor released from lenvatinib‐resistant hepatocellular carcinoma promotes malignant behavior and drug resistance through tumor‐associated macrophages
  di: Yukako Takehara, et al.
  Pubblicazione: (2025)